Immunology
Chronic Granulomatous Disease (CGD)
7
Pipeline Programs↗
3
Active Trials↗
6
Companies Involved↗
Chronic Granulomatous Disease (CGD) is an early-stage landscape with 7 programs across 6 companies. The most active players are Akero Therapeutics, Roche, GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
7programs
Small molecule457%
Protein / enzyme229%
Monoclonal antibody114%
Modality classified for 88% of 8 pipeline programs.
Analysis
Trial Status
3
clinical trials
Recruiting2 · 67%
Enrolling by invitation1 · 33%
Clinical Trials
Trial Activity
Screening and Baseline Assessment of Patients With Abnormalities of Immune Function
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00128973·3,500 enrolled
Part B- Phase I/II, Non-Randomized, Single Site Study, Open-label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Enrolling by invitation·National Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT07113743·10 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)